| Bioactivity | CCT239065 is an orally available, effective inhibitor of the mutant protein kinase V600EBRAF (RAF) with anti-tumor activity. CCT239065 inhibits downstream signaling of V600EBRAF in cancer cells, blocking DNA synthesis and suppressing proliferation[1][2]. |
| CAS | 1163719-51-4 |
| Formula | C29H29N7O3S |
| Molar Mass | 555.65 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Steven Whittaker, et al. A Novel, Selective, and Efficacious Nanomolar Pyridopyrazinone Inhibitor of V600EBRAF. Cancer Res. 2010 Oct 15;70(20):8036-44. [2]. James A McCubrey, et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget. 2012 Oct;3(10):1068-111. |
CCT239065
CAS: 1163719-51-4 F: C29H29N7O3S W: 555.65
CCT239065 is an orally available, effective inhibitor of the mutant protein kinase V600EBRAF (RAF) with anti-tumor activ
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.